secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bone Biologics Corp (BBLG)
CIK:        0001419554
Form:       8-K
Filed at:   2024-03-01T23:59:59+00:00
Accession:  0001493152-24-008412
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bone Biologics reports NB1 clinical trial progress: 3 sites engaged in Australia
--------------------------------------------------------------------------------

- NB1 pilot trial: 30 adults, randomized, evaluating safety & effectiveness in TLIF for DDD.
- Three Australian hospital sites engaged after HREC approval; study design reviewed by FDA.
- Inclusion: DDD at one level L2-S1, up to Grade 1 spondylolisthesis or retrolisthesis.
- Progress supports advancement toward potential US pivotal trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419554/000149315224008412/0001493152-24-008412-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419554/000149315224008412/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-008412

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer